BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
📌 TL;DR
GTC 2026 kicks off: Roche claims pharma's largest GPU footprint (3,500+ Blackwell chips); Lilly showcases LillyPod; Jensen Huang keynote sets AI-in-pharma tone
Rhythm PDUFA Friday: Imcivree decision for acquired hypothalamic obesity lands March 20
ACIP meets Wednesday-Thursday: Kennedy-era committee to debate COVID vaccine injuries; ~30 states have already decoupled from CDC guidance
Linerixibat PDUFA next week: Alfasigma-controlled asset gets FDA verdict March 24
⚡ Executive Takeaway
The pharma GPU arms race went vertical yesterday. Roche announced 2,176 new Blackwell GPUs—bringing its total to 3,500+—claiming the industry's largest compute footprint. Lilly countered that its LillyPod (1,016 Blackwell Ultra chips) is the most powerful wholly owned AI factory in biopharma. Different benchmarks, same message: wet-lab throughput is no longer the bottleneck. Dry-lab simulation is. The companies running the biggest models fastest will compress discovery timelines—or at least that's the bet. Diogo Rau's warning at Lilly's launch is worth remembering: "The hype is actually a serious threat to the research itself." 👉 Read Full Analysis
🔮 What To Watch
Date | Event | Why It Matters |
|---|---|---|
March 18-19 | ACIP Meeting (Virtual) | First Kennedy-era meeting with COVID vaccine injury agenda; AAP lawsuit pending |
March 20 | Rhythm Imcivree PDUFA | Acquired hypothalamic obesity sNDA; Phase 3 showed 16.5% BMI reduction |
March 24 | GSK/Alfasigma linerixibat PDUFA | Cholestatic pruritus in PBC; GLISTEN Phase 3 hit endpoints |
March 26 | Novo Nordisk AGM | Board elections amid -34% Holdings asset decline; GLP-1 defense under scrutiny |
March 28 | Rocket Pharma Kresladi PDUFA | LAD-I gene therapy; 100% OS at 12 months; PRV eligible |
🚀 Today's Top Story
Pharma's GPU Arms Race Escalates at GTC 2026
NVIDIA's annual GPU Technology Conference opened in San Jose yesterday with a pharma subplot: Roche and Lilly are now locked in a compute-capacity measuring contest.
Roche (March 16):
Deployed 2,176 new NVIDIA Blackwell GPUs across U.S. and European sites
Combined on-premise + cloud footprint now exceeds 3,500 GPUs
Claims "greatest announced GPU footprint available to a pharmaceutical company"
Using BioNeMo platform for biological foundation models; Omniverse for manufacturing digital twins
One application already live: digital twin of Roche's new GLP-1 manufacturing facility in North Carolina
Lilly (announced Feb 26; showcased at GTC):
LillyPod uses 1,016 Blackwell Ultra GPUs in a DGX SuperPOD
Claims "most powerful AI factory wholly owned and operated by a pharmaceutical company"
9,000+ petaflops of AI performance; built in four months in Indianapolis
Dry lab can simulate "billions of molecular hypotheses simultaneously" vs. ~2,000 molecules/year in traditional wet labs
The gap with hyperscalers remains vast. xAI's Colossus cluster runs 500,000+ GPUs. Meta's Louisiana facility is targeting millions. But within pharma, the GPU buildout is accelerating—Roche, Lilly, and Recursion now collectively deploy 5,000+ chips.
What matters for investors: Neither company has tied a specific clinical candidate to its AI infrastructure yet. The first credible "AI-discovered, AI-accelerated" approval will be the proof point. Until then, these are expensive positioning bets.
🧬 AI & Digital Health
Jensen Huang Keynote Highlights (March 16)
Framed the "token" as the basic unit of modern AI—from scientific discovery to robotics
NVIDIA Vera CPU launched: purpose-built for agentic AI and reinforcement learning
NVIDIA Vera Rubin platform: seven new chips in full production for AI factory scale-up
Kimberly Powell (NVIDIA VP, Healthcare/Life Sciences) Session
Nearly 90% of eligible small molecule programs at Genentech now integrate AI
One oncology molecule designed 25% faster; backup candidate delivered in 7 months
Expects AI-assisted discovery benefits to materialize around 2030
🏢 Corporate Developments
TrumpRx Expansion
GSK and Amgen formally added to TrumpRx.gov last week, bringing total to 54 medications from 6 manufacturers
Amgen offering Amjevita at ~80% off retail ($299 vs. $1,484); Aimovig and Repatha at 62% discounts
GSK listing Incruse (55% off), Arnuity, Relenza, and Anoro (10-51% off)
Total TrumpRx participants now include: Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, EMD Serono, GSK, Amgen
China BCI Milestone (March 13)
NMPA approved Neuracle Technology's implantable brain-computer interface—first commercial BCI approval globally
Indicated for adults 18-60 with cervical spinal cord injury quadriplegia
Coin-sized device on brain surface controls pneumatic glove for grasping
36-patient trial: 100% achieved home-based brain-controlled grasp; no device-related SAEs reported
Chinese BCI funding surge: StairMed raised $72.8M (Alibaba-led); Gestala raised $21.6M
📅 Week Ahead: Key Catalysts
Wednesday-Thursday: ACIP Meeting
The CDC's Advisory Committee on Immunization Practices meets virtually March 18-19. Agenda includes:
COVID-19 vaccine injuries and Long-COVID discussions
ACIP recommendation methodology changes
Potential votes on all three items
Context: This is the first meeting since RFK Jr. replaced all committee members last summer. The American Academy of Obstetricians & Gynecologists withdrew as a liaison member, citing concerns about "cherry-picking of data." An AAP lawsuit sought to stop the meeting. ~30 states have already decoupled from CDC vaccine guidance.
Friday: Rhythm Imcivree PDUFA (March 20)
Indication: Acquired hypothalamic obesity (AHO) sNDA
Phase 3 TRANSCEND results: 16.5% BMI reduction (setmelanotide) vs. +2.4% (placebo) at 52 weeks; 80% responders achieved >5% BMI reduction
Commercial prep: Sales force expanded from 16 to 42 reps; in-field since October 2025
Addressable market: ~25,000-28,000 patients globally; company has identified 2,000+ suspected/diagnosed AHO patients in tier 1-2 practices
Monday: GSK/Alfasigma Linerixibat PDUFA (March 24)
Indication: Cholestatic pruritus in primary biliary cholangitis (PBC)
Phase 3 GLISTEN: Met primary and key secondary endpoints; rapid, sustained improvement in itch and sleep interference
Deal structure: GSK receives $300M upfront + $100M on FDA approval; Alfasigma controls post-approval commercialization
Orphan Drug Designation: U.S., EU, Japan
Wednesday: Novo Nordisk AGM (March 26)
Location: Bella Center, Copenhagen, 14:00 CET
Key context: Novo Holdings assets declined 34% ($160B → $107B); NVO down ~24% YTD; weaker-than-expected 2026 guidance citing pricing pressure and competition
Board elections: All shareholder-elected members up for re-election; three new nominees proposed
Friday: Rocket Pharma Kresladi PDUFA (March 28)
Indication: Severe Leukocyte Adhesion Deficiency Type I (LAD-I)
Mechanism: Lentiviral gene therapy delivering functional ITGB2 gene
Phase 1/2 data: 100% overall survival at 12 months (and through entire follow-up); all primary/secondary endpoints met; no treatment-related SAEs
Prior CRL (June 2024): CMC-related; company aligned with FDA on "limited" additional information
PRV eligible: If approved, Rocket receives Rare Pediatric Disease Priority Review Voucher
🔒 BioMed Nexus Pro — Institutional Intelligence Brief
In Today's Pro Brief:
🧠 Institutional Read-Through: Why Roche's hybrid-cloud claim and Lilly's wholly-owned claim both matter—and why neither proves anything yet
⚖️ ACIP Risk Framing: Scenario analysis for Wednesday's meeting; what a vote on methodology changes could mean for vaccine reimbursement
📊 Rhythm Positioning: Pre-PDUFA option flows and what the setup suggests about Street expectations
💰 Linerixibat Deal Anatomy: Why GSK is exiting hepatology (except HBV/MASH/ALD) and what Alfasigma's Intercept acquisition signals about PBC market structure
Selective 2026 sponsorship placements are available
Reply directly to discuss a partnership or submit an inquiry here